CATALYST PHARMACEUTICALS, INC. (CPRX) Q3 2025 10-Q Quarterly Report
CATALYST PHARMACEUTICALS, INC. (CPRX) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 5, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
CATALYST PHARMACEUTICALS, INC. Q3 2025 10-Q Analysis
Management Discussion & Analysis
- • No quarterly revenue or YoY financial figures provided in text
- • No profitability or margin data included in MD&A section
- • No segment or product line performance metrics disclosed
- • No cash position, operating cash flow, or capital deployment details mentioned
- • Management highlights potential tariffs on pharmaceutical imports, risks to supply chain costs, and impact on clinical trials and product sales
- • President Trump's MFN pricing proposals may affect drug pricing for Medicaid and Medicare with uncertain financial impact
Risk Factors
- • New risk: generic competition for FYCOMPA® tablets began entering market, threatening revenue and potential intangible asset impairment
- • Updated legal risk: ongoing litigation enforcement against Paragraph IV challenger seeking generic FIRDAPSE® entry intensified
- • Regulatory risk: pricing pressures from Inflation Reduction Act of 2022 and potential Most Favored Nation pricing or 100% tariffs on imports
- • Operational risk: reliance on third party suppliers and contract manufacturers maintaining cGMP and timely product supply
- • Financial risk: uncertainty in payor coverage and reimbursement levels impacting product pricing and revenue realization
CATALYST PHARMACEUTICALS, INC. Q3 2025 Quarterly FinancialsXBRL
Revenue
$148M
▲ +15.3% YoY▲ +1.2% QoQ
Net Income
$53M
▲ +20.3% YoY▲ +1.3% QoQ
Operating Margin
44.7%
▲ +510bp YoY▼ -58bp QoQ
Net Margin
35.6%
▲ +147bp YoY▲ +2bp QoQ
ROE
5.7%
Total Assets
$1.1B
EPS (Diluted)
$0.41
▲ +17.1% YoY▼ 0.0% QoQ
Operating Cash Flow
$32M
▼ -55.5% YoY▼ -54.5% QoQ
Source: XBRL data from CATALYST PHARMACEUTICALS, INC. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on CATALYST PHARMACEUTICALS, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.